Arrhythmic mitral valve prolapse (aMVP) is associated with malignant ventricular arrhythmias (VA) despite the absence of significant mitral regurgitation (MR) or left ventricular (LV) dysfunction. Advances in cardiovascular magnetic resonance (CMR) provided opportunities to implement a-MVP characterization. Howev...
S. Di Maio, F. Deharo, H. Zaidi et al.· European Heart Journal· 0 citations
Arrhythmogenic mitral valve prolapse (aMVP) has been associated with malignant ventricular arrhythmias and sudden cardiac death(1). Whether aMVP represents a distinct genetic entity or reflects phenotypic overlap with underlying cardiomyopathic or inherited arrhythmia substrates remains unclear.
To evaluat...
K. Galanti, G. Sharaf Dabbagh, K. Hesse et al.· European Heart Journal· 0 citations
Risk stratification for sudden cardiac death (SCD) in non-ischemic cardiomyopathy (NICM) remains suboptimal. Current guidelines recommend primary prevention implantable cardioverter-defibrillator (ICD) implantation in patients with LVEF <35% (NYHA II–III) (1); however, its limited predictive accuracy (2,3) unders...
A. Latini, G. Falasconi, C. Panico et al.· European Heart Journal· 0 citations
Conventional cardiovascular risk scores estimate the probability of future events; however, these risk scores do not directly quantify the presence or extent of subclinical atherosclerosis. This narrative review critically evaluates the current evidence on the carotid plaque score (CPS), a semiquantitative ultrasound-b...
D. Sulman, S. Cacciatore, Marco Bernardi et al.· Reviews in cardiovascular me...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.